Literature DB >> 28627403

Accepting Hearts From Hepatitis C-Positive Donor: Can We Expand the Donor Pool?

Jonathan Grinstein1, Laura M Lourenco1, Helen S Te1, John F Renz2, Valluvan Jeevanandam2, Nir Uriel3.   

Abstract

BACKGROUND: Until recently, transplantation from hepatitis C-positive donors was relatively contraindicated as eradication of active hepatitis C previously required an interferon-based regimen that has been associated with rejection in solid organ transplantation. New interferon-free treatment regimens for hepatitis C have fewer adverse events and higher cure rates than interferon-based regimens. Interferon-free regimens have been shown to be safe in the liver transplantation literature, but little is known about the safety and efficacy of treatment in heart transplantation. CASE DESCRIPTION AND DISCUSSION: Here we report a case of successful eradication of hepatitis C with a non-interferon-based regimen using ledipasvir-sofosbuvir following combined orthotopic heart and liver transplantation. Based on the prevalence of hepatitis C in the general population, inclusion of hepatitis C-positive donors for heart transplantation can expand this component of the donor pool 3- to 6-fold.
CONCLUSIONS: In carefully selected patients and recipients, inclusion of hepatitis C-positive donors may allow for expansion of the donor pool.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Donor pool; OHT/OLT; hepatitis C; ledipasvir-sofosbuvir

Mesh:

Substances:

Year:  2017        PMID: 28627403      PMCID: PMC5741441          DOI: 10.1016/j.cardfail.2017.05.018

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  6 in total

1.  Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient.

Authors:  Bing-Yen Wang; Hsiao-Huang Chang; I-Ming Chen; Chun-Che Shih; An-Hang Yang
Journal:  Ann Thorac Surg       Date:  2010-05       Impact factor: 4.330

Review 2.  Evolving epidemiology of hepatitis C virus.

Authors:  D Lavanchy
Journal:  Clin Microbiol Infect       Date:  2011-02       Impact factor: 8.067

3.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

4.  Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients.

Authors:  Abdulrahman A Aljumah; Mohamed A Saeed; Ahmed I Al Flaiw; Ibrahim H Al Traif; Abduljaleel M Al Alwan; Salem H Al Qurashi; Ghormallah A Al Ghamdi; Fayez F Al Hejaili; Mohammed A Al Balwi; Abdulla A Al Sayyari
Journal:  World J Gastroenterol       Date:  2012-01-07       Impact factor: 5.742

5.  Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C.

Authors:  Faisal M Sanai; Dujana Mousa; Abdallah Al-Mdani; Ghada Al-Shoail; Hamad Al-Ashgar; Khalid Al Meshari; Ahmed Al-Qahtani; Mayssa Saadeh; Khalid I Bzeizi; Hassan Aleid
Journal:  J Hepatol       Date:  2013-02-18       Impact factor: 25.083

6.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

  6 in total
  2 in total

1.  Heart Transplantation From Hepatitis C-Positive Donors in the Era of Direct Acting Antiviral Therapy: A Comprehensive Literature Review.

Authors:  Schnegg Bruno; Bart Nicole; Dharan Nila J; Matthews Gail; Nadel James; Macdonald Peter S; Hayward Christopher S
Journal:  Transplant Direct       Date:  2019-08-23

Review 2.  The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients.

Authors:  Robert L Gottlieb; Shelley A Hall
Journal:  Curr Transplant Rep       Date:  2018-04-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.